TY - JOUR
T1 - Barriers to the successful treatment of liver disease by hepatocyte transplantation
AU - Soltys, Kyle A.
AU - Soto-Gutiérrez, Alejandro
AU - Nagaya, Masaki
AU - Baskin, Kevin M.
AU - Deutsch, Melvin
AU - Ito, Ryotaro
AU - Shneider, Benjamin L.
AU - Squires, Robert
AU - Vockley, Jerry
AU - Guha, Chandan
AU - Roy-Chowdhury, Jayanta
AU - Strom, Stephen C.
AU - Platt, Jeffrey L.
AU - Fox, Ira J.
N1 - Funding Information:
This work was supported by NIH Grants HL52297 (J.L.P.), DK048794 , and AI049472 (I.J.F.).
PY - 2010/10
Y1 - 2010/10
N2 - Treatment of patients with liver disease by hepatocyte transplantation has expanded dramatically over the last decade, especially for treatment of patients with liver-based metabolic disorders. While much progress has been made, full realization of its potential has not been reached. Treatment of acute liver failure has been hampered by a number of factors, but the efficacy of hepatocyte transplantation in treating this entity could be better determined through a multi-institutional trial using a uniform and standardized treatment strategy. The barriers to treating chronic liver failure resulting from cirrhosis are more extensive. Novel strategies are being developed to safely precondition patients with liver-directed radiation therapy in order to enhance donor hepatocyte survival, long-term engraftment and improve treatment of patients with life-threatening liver-based genetic deficiencies. This work could soon be translated to the clinic. Once hepatocyte transplantation has been shown to effectively replace organ transplantation for a portion of patients with liver failure and life-threatening liver metabolic diseases, it is likely that multiple novel sources of donor hepatocytes will be developed, making cell therapy available and effective for a broad population of patients with liver disorders.
AB - Treatment of patients with liver disease by hepatocyte transplantation has expanded dramatically over the last decade, especially for treatment of patients with liver-based metabolic disorders. While much progress has been made, full realization of its potential has not been reached. Treatment of acute liver failure has been hampered by a number of factors, but the efficacy of hepatocyte transplantation in treating this entity could be better determined through a multi-institutional trial using a uniform and standardized treatment strategy. The barriers to treating chronic liver failure resulting from cirrhosis are more extensive. Novel strategies are being developed to safely precondition patients with liver-directed radiation therapy in order to enhance donor hepatocyte survival, long-term engraftment and improve treatment of patients with life-threatening liver-based genetic deficiencies. This work could soon be translated to the clinic. Once hepatocyte transplantation has been shown to effectively replace organ transplantation for a portion of patients with liver failure and life-threatening liver metabolic diseases, it is likely that multiple novel sources of donor hepatocytes will be developed, making cell therapy available and effective for a broad population of patients with liver disorders.
KW - Hepatocyte transplantation
UR - http://www.scopus.com/inward/record.url?scp=77956265180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956265180&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2010.05.010
DO - 10.1016/j.jhep.2010.05.010
M3 - Comment/debate
C2 - 20667616
AN - SCOPUS:77956265180
SN - 0168-8278
VL - 53
SP - 769
EP - 774
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 4
ER -